UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 18,
2021
PDS BIOTECHNOLOGY CORPORATION
(Exact Name of Registrant as Specified in Charter)
Delaware
|
001-37568
|
26-4231384
|
|
|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
25B Vreeland Road, Suite
300, Florham Park, NJ 07932
(Address of Principal Executive Offices, and Zip Code)
(800)
208-3343
Registrant’s Telephone Number, Including Area Code
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see
General Instruction A.2. below):
| |
☐
|
Written communication pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
☐ |
Pre-commencement communication pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
☐ |
Pre-commencement communication pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
Common Stock, par value $0.00033 per share
|
PDSB
|
The Nasdaq
Capital Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17
CFR
§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR
§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Yes ☐
No ☐
On October 18, 2021, PDS Biotechnology Corporation updated its
corporate presentation slide deck. A copy of the slide deck
is filed as Exhibit 99.1 hereto and incorporated by reference
herein.
|
Item 9.01 |
Financial Statements and Exhibits.
|
(d) Exhibits.
|
Exhibit
Number
|
|
Description
|
|
|
|
|
|
|
|
Corporate Presentation October 2021.
|
|
104
|
|
Cover Page Interactive Data File - the cover page interactive date
file does not appear in the Interactive Date File because its XBRL
tags are embedded within the Inline XBRL document.
|
Signature
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
| |
|
PDS BIOTECHNOLOGY CORPORATION
|
| |
|
|
|
Date: October 18, 2021
|
|
By:
/s/ Frank Bedu-Addo, Ph.D.
|
|
|
Name: Frank Bedu-Addo, Ph.D.
|
|
|
Title: President and Chief Executive Officer
|